Drug Profile
Research programme: amyloid oligomer therapeutics - Kinexis
Alternative Names: Amyloid oligomer small molecule; Amyloid oligomer vaccine; Anti-amyloid oligomer MAb; Anti-amyloid oligomer monoclonal antibodyLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of California at Irvine
- Class Monoclonal antibodies; Small molecules; Vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)